Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are characterized by increased pulmonary and systemic inflammation and commonly caused by bacterial and/or viral infection. Little is known about the T-cell dysregulation in AECOPD that promotes these outcomes.
Introduction
Chronic obstructive pulmonary disease (COPD) is amongst the top five causes of global morbidity and mortality. COPD is characterized by chronic airway and systemic inflammation and so predisposes patients to ischemic heart disease, vascular disease, muscle wasting and cachexia [1, 2] .
COPD patients may also experience acute exacerbations (AECOPD), commonly caused by infections [3] . AECOPD can accelerate the decline in lung function [4] , but the associated immune dysregulation is not well understood. AECOPD may be an immune-deficient state reflecting an impaired T-helper type I (Th1) responses to infectious agents (e.g. decreased production of IFNγ) [5] [6] [7] [8] [9] . There are several anti-inflammatory molecules, including CD39 that may be highly expressed in AECOPD that may inhibit IFNγ responses.
CD39 is an ectonucleotidase which generates adenosine monophosphate (AMP) from adenosine triphosphate/adenosine diphosphate (ATP/ADP). CD73 (another ectonucleotidase) then converts AMP to adenosine, an anti-inflammatory molecule that can inhibit the function of CD4 + and CD8 + T-cells and natural killer cells [10] . CD39 is highly expressed by regulatory T-cells (Tregs) and is important for their immune-suppressive function [11, 12] . Inflammation usually results in the release of ATP that is converted to adenosine by Tregs via the CD39/CD73 pathway. The binding of adenosine to A2A receptors downregulates the activity of effector T-cells but promotes the expansion of Tregs and their suppression of effector T-cell proliferation [13] .
Therefore, CD39 and CD73 are important in the regulation of immune responses by inhibiting the ATP-driven pro-inflammatory immune cell activity and promote an anti-inflammatory state mediated by adenosine [10] . Since AECOPD may be an immunodeficient state, we hypothesized that chronic inflammation induces the expression of CD39 that then inhibits protective effector T-cell responses (e.g. IFNγ production) against bacteria in AECOPD.
Immunoregulatory role of CD39 in COPD 2. Material and methods
Study subjects
AECOPD patients (n=21) admitted to the Royal Perth Hospital Emergency Department (Western Australia) were recruited. Stable COPD (sCOPD) patients who were previous smokers (>15 packyears and ceased smoking >5 years earlier) from a dedicated Royal Perth Hospital COPD clinic (n=33) and healthy age-matched, non-smoking subjects with no clinical evidence of COPD were also included as controls (n=33). The diagnosis and severity of COPD was categorised by a respiratory physician according to the GOLD criteria (Stages 2-4). All patients had been treated with anticholinergic drugs, long-acting beta agonists and inhaled corticosteroids but none were receiving systemic corticosteroids or had diabetes, neuromuscular, allergic or rheumatological disease at the time of sampling. The study was approved by the Ethics Committee at the Royal Perth Hospital and all participants gave informed consent.
Sample and data collection
Peripheral blood mononuclear cells (PBMC) were isolated from blood collected in lithium heparin tubes by Ficoll gradient centrifugation and cryopreserved in 10% dimethyl sulfoxide/fetal calf serum.
Plasma Intracytoplasmic staining was performed using the BD Pharmingen TM FoxP3 buffer set and FoxP3-PE antibody (BD Biosciences). 200,000 events were acquired using a BD FACSCanto II cytometer and analyses were done with FlowJo v5.7.2 software (Tree Star, Ashland, OR). Gating for T-cell subsets and expression of CD39 is shown in Figure 1 . Concentrations of IFNγ, TNFα, IL-6, IL-10 (BD Biosciences) and IL-17 (eBioscience, San Diego, CA) were measured by ELISA in supernatants from PBMC (2x10 6 cells/mL) cultured with SEB (1μg/mL; Sigma-Aldrich, St. Louis, MO) for 24hr.
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Data Analysis
Non-parametric Mann-Whitney tests were used to compare groups. Correlations were assessed using Spearman's rank correlation coefficient. Statistical analyses were performed with Graphpad Prism 5.04 software (La Jolla, CA). Statistically significant differences (p<0.05) are indicated in the figures and p=0.05-0.10 is noted as marking a trend. 
Results
AECOPD patients exhibited systemic inflammation but decreased SEB-induced
Expression of CD39 on T-cells correlates directly with plasma sTNFR and inversely with IFNγ production by T-cells
Proportions of circulating CD39 + CD4 + and CD8 + T-cells, Tregs (Foxp3 + CD4 + T-cells) and nonTregs (Foxp3 -CD4 + T-cells) were higher in AECOPD patients than sCOPD patients ( Figure 3A ).
Compared to healthy controls, AECOPD patients exhibited increased proportion of CD39 + CD8 + T- (Figure 3 , B-E), but not with levels of TNFα, IL-6, IL-17 and IL-10 (data not shown).
Discussion
This study describes for the first time the expression of CD39 on circulating T-cell subsets in relation Increased numbers of CD39 + cells that may provide anti-inflammatory functions have been isolated in inflammatory sites such as joints of arthritic patients [14] , bronchoalveolar lavage from COPD patients [15] , and lamina propria of patients with Crohn's disease [16] . Circulating antigen-reactive CD4 + T-cells expressing CD39 were also increased in patients with active rather than latent tuberculosis [17] . There is growing evidence to suggest that CD39 inhibits IFNγ production. Notably depletion of CD39 + Treg increased TB-specific antigen responses [18] . Furthermore, Bai et al demonstrated that CD39 + CD8 + T-cells inhibited IFNγ production by CD39 -CD8 + T-cells from healthy control samples [16] .
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Increased expression of CD39 has also been associated with other markers of T-cell exhaustion or dysfunction. This includes increased expression of PD-1 paralleling the decreased expression of CD28 and production of IFNγ [19] . In our patient cohort, we correlated increased CD28 null T-cells in COPD and AECOPD with CMV-IgG titres [20] . Our results build on the work by Lazar et al (2015) showing increased expression of CD39 on cells from bronchoalveolar lavage fluid and sputum of ex-smoking COPD patients than smokers and nonsmoking controls [15] . They demonstrated that cigarette smoking induces the expression of CD39 on bronchoalveolar lavage cells and lung tissue, and proposed a compensatory upregulation of CD39 as a protective mechanism in cigarette smoke-induced lung damage. Our data suggests that the increased CD39 expression is not only limited to the lung environment but is also evident systemically, possibly as a compensatory response to chronic inflammation in COPD resulting in poorer T-cell responses.
Blockade of CD39 may restore T-cell responses, but abrogation of CD39 in knockout mice promoted emphysema [15] , and cigarette smoke can reduce CD39 expression in the lung, macrophages and vascular endothelial cells [21] . Therefore, further studies and refinements are required before CD39
is accepted as an appropriate theraupeutic target,. 
